These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 20957337)
1. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337 [TBL] [Abstract][Full Text] [Related]
2. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235 [TBL] [Abstract][Full Text] [Related]
3. Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy. Ming J; Sun B; Li Z; Lin L; Meng X; Han B; Wang R; Wu P; Li J; Cai J; Jiang C Aging (Albany NY); 2017 Apr; 9(4):1233-1247. PubMed ID: 28446712 [TBL] [Abstract][Full Text] [Related]
4. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Short SC; Giampieri S; Worku M; Alcaide-German M; Sioftanos G; Bourne S; Lio KI; Shaked-Rabi M; Martindale C Neuro Oncol; 2011 May; 13(5):487-99. PubMed ID: 21363882 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Munoz JL; Rodriguez-Cruz V; Ramkissoon SH; Ligon KL; Greco SJ; Rameshwar P Oncotarget; 2015 Jan; 6(2):1190-201. PubMed ID: 25595896 [TBL] [Abstract][Full Text] [Related]
6. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. Blough MD; Beauchamp DC; Westgate MR; Kelly JJ; Cairncross JG J Neurooncol; 2011 Mar; 102(1):1-7. PubMed ID: 20593219 [TBL] [Abstract][Full Text] [Related]
7. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Gilbert CA; Daou MC; Moser RP; Ross AH Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377 [TBL] [Abstract][Full Text] [Related]
8. Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression. Jiang C; Shen F; Du J; Fang X; Li X; Su J; Wang X; Huang X; Liu Z Biomed Pharmacother; 2018 Jan; 97():844-850. PubMed ID: 29136760 [TBL] [Abstract][Full Text] [Related]
10. Glioblastoma stem cells resistant to temozolomide-induced autophagy. Fu J; Liu ZG; Liu XM; Chen FR; Shi HL; Pangjesse CS; Ng HK; Chen ZP Chin Med J (Engl); 2009 Jun; 122(11):1255-9. PubMed ID: 19567133 [TBL] [Abstract][Full Text] [Related]
11. LncRNA-XIST interacts with Du P; Zhao H; Peng R; Liu Q; Yuan J; Peng G; Liao Y Biosci Rep; 2017 Oct; 37(5):. PubMed ID: 28831025 [TBL] [Abstract][Full Text] [Related]
12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
13. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide. Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167 [TBL] [Abstract][Full Text] [Related]
15. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells. Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773 [TBL] [Abstract][Full Text] [Related]
16. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. Marín-Ramos NI; Thein TZ; Cho HY; Swenson SD; Wang W; Schönthal AH; Chen TC; Hofman FM Mol Cancer Ther; 2018 Mar; 17(3):625-637. PubMed ID: 29440289 [TBL] [Abstract][Full Text] [Related]
17. Co-expression of Cytoskeletal Protein Adducin 3 and CD133 in Neurospheres and a Temozolomide-resistant Subclone of Glioblastoma. Poon MW; Zhuang JT; Wong ST; Sun S; Zhang XQ; Leung GK Anticancer Res; 2015 Dec; 35(12):6487-95. PubMed ID: 26637861 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study. Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131 [TBL] [Abstract][Full Text] [Related]
19. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. Chen CC; Taniguchi T; D'Andrea A J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219 [TBL] [Abstract][Full Text] [Related]
20. CXCR4-positive subset of glioma is enriched for cancer stem cells. Zheng X; Xie Q; Li S; Zhang W Oncol Res; 2011; 19(12):555-61. PubMed ID: 22812188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]